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Effect of candesartan cilexetil (TCV-116) in rats with chronic sive renal failure, as Ang II not only contributes to glo-
renal failure. merular capillary hypertension, but also has a direct in-
Background. Inhibition of the renin-angiotensin system by fluence on some functions of the mesangial cells and theboth angiotensin II type 1 receptor antagonists (AT1As) and glomerular filtration barrier [2, 3]. In fact, inhibition ofangiotensin I-converting enzyme inhibitors (ACEIs) shows re-
the RAS by Ang II type 1 receptor antagonists (AT1As)noprotective effects in rats with chronic renal failure when
treatment is started in the early phase of renal injury. In this or Ang I-converting enzyme inhibitors (ACEIs) has been
study, we examined the renal protective effects of candesartan shown to have renoprotective effects in animal models
cilexetil (TCV-116), an AT1A, and enalapril, an ACEI, in the with renal diseases and in patients with chronic renalprogressive phase of renal injury in 5/6 nephrectomized rats.
failure or diabetic nephropathy [4–11].Methods. Candesartan cilexetil (1 mg/kg/day) and enalapril
Both AT1As and ACEIs ultimately block the RAS,(10 mg/kg/day) were orally administered once a day for 4 weeks
(the short-term experiment) or 16 weeks (the long-term experi- but the mechanism of the RAS inhibition is different.
ment) to 5/6 nephrectomized rats beginning 15 weeks after the Namely, AT1As selectively inhibit the binding of Ang II
nephrectomy, that is, after they had already showed marked to AT1 receptors, resulting in increasing plasma Ang IIproteinuria.
and renin levels [12]. The increased Ang II may act onResults. In vehicle-treated rats, proteinuria, glomeruloscle-
an Ang II type 2 (AT2) receptor, a counter receptor forrosis, and interstitial fibrosis developed. Moreover, enhanced
expression of transforming growth factor-b1 (TGF-b1) in the AT1 receptors [13], and the activated AT2 receptor is
injured glomeruli was observed. These adverse changes pro- thought to contribute to the effects of AT1As. In contrast,
gressed with time, and in the short-term experiment, both drugs ACEIs inhibit Ang I-converting enzyme (ACE), which
inhibited them. In the long-term experiment, the progressive
also degrades bradykinin (BK), resulting in elevatingproteinuria and the elevation of blood pressure were similarly
plasma renin levels and kinin activities, as well as de-attenuated by both drugs. However, candesartan cilexetil sig-
creasing plasma Ang II levels [14, 15]. BK is thoughtnificantly inhibited the progression of glomerulosclerosis, the
expression of TGF-b1, and interstitial fibrosis, whereas enala- to contribute to the effects of ACEIs via nitric oxide,
pril did not. endothelium-derived hyperpolarizing factor, and eicosa-
Conclusion. These results indicate that candesartan cilexetil noid production [16]. All of this evidence seems to indi-shows potent and long-term preventive effects against the pro-
cate the existence of some differences between the phar-gression of previously developed renal injury.
macological effects of AT1As and ACEIs; however, it
remains unclear which kind of RAS blocker has more
beneficial effects in various diseases, including renal dis-Glomerular capillary hypertension is associated with
eases.progressive renal failure [1]. Angiotensin II (Ang II),
Recent studies have raised some doubts as to the long-the primary effector product of the renin-angiotensin
term efficacy of ACEIs, especially in post-treatmentsystem (RAS), is thought to be a crucial factor in progres-
studies [17, 18]. Perico et al reported that in streptozo-
tocin-induced diabetic rats, moexipril, an ACEI, com-
pletely prevented the progression of glomerulosclerosisKey words: renoprotection, angiotensin II receptor antagonist, ne-
phrectomy, progressive renal disease, injury, ACE inhibitor. when it was administered in the early phase of pathogen-
esis but that the compound did not prevent it whenReceived for publication June 16, 1998
treatment was started during the progressive phase withand in revised form April 15, 1999
Accepted for publication April 24, 1999 marked proteinuria [17]. Verseput et al reported that
in spontaneously hypertensive fawn-hooded rats, which 1999 by the International Society of Nephrology
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Fig. 1. Schematic presentation of the experi-
mental protocol.
develop proteinuria and renal damage, early stage treat- p.o., N 5 7), and enalapril-treated (10 mg/kg, p.o., N 5
7) 5/6 NX rats, as well as sham-operated normal two-ment with the ACEI lisinopril completely protected
against glomerulosclerosis, whereas the compound did kidney rats (N 5 5). At the onset of the both experi-
ments, NX rats were divided into three groups withnot prevent further development of glomerulosclerosis
when it was administered in the progressive phase of equivalence of the values of urinary albumin excretion,
urinary protein excretion, creatinine clearance (CCr), andglomerulosclerosis, despite fine control of both the
systemic blood pressure and glomerular capillary pres- blood pressure to ensure equal severity of lesions in the
remnant kidney. A one-way analysis of variance wassure [18].
The 5/6 nephrectomized (5/6 NX) rat has commonly used to confirm the equal initial values of the previously
mentioned four parameters in the both experiments. Atbeen used as a model to investigate the effects of drugs
on pathophysiological events in the progression of glo- the onset of intervention in the short-term experiment,
urinary total protein was 86.6 6 9.8, 89.4 6 11.1, andmerulosclerosis. These rats also show renal functional
88.6 6 9.4 mg/day (P 5 0.981). Urinary albumin wasand structural changes similar to those observed in pa-
38.3 6 8.3, 39.0 6 9.1, and 38.4 6 8.2 mg/day (P 5 0.998).tients with end-stage kidney disease. This evidence
CCr was 0.25 6 0.02, 0.24 6 0.02, and 0.26 6 0.03 ml/prompted us to compare the renal protective effects of
min/100 g body wt (P 5 0.803). Blood pressure waslong-term treatment with candesartan cilexetil (TCV-
145.4 6 4.5, 143.6 6 3.5, and 144.2 6 6.0 mm Hg (P 5116) [19–21], an AT1A, and enalapril, an ACEI, in the
0.964) in the vehicle-treated, candesartan cilexetil-progressive phase of renal injury in 5/6 NX rats. To
treated, and enalapril-treated groups, respectively. Atevaluate the effect of post-treatment, these drugs were
the onset of the intervention in the long-term experi-administered to the rats 15 weeks after the nephrectomy,
ment, urinary total protein was 89.3 6 9.7, 85.9 6 11.6,that is, after they had already developed renal damage.
and 89.8 6 15.5 mg/day (P 5 0.971). Urinary albumin
was 39.0 6 8.1, 39.3 6 7.1, and 39.0 6 9.5 mg/day (P 5
METHODS
0.999). CCr was 0.23 6 0.01, 0.24 6 0.02, and 0.23 6 0.01
Experimental design ml/min/100 g body wt (P 5 0.998). Blood pressure was
149.9 6 2.7, 145.0 6 4.1, and 143.0 6 4.4 mm Hg (P 5Male five-week-old Sprague-Dawley rats, purchased
from Japan Clea Laboratory (Tokyo, Japan), were sub- 0.444) in vehicle-treated, candesartan cilexetil-treated,
and enalapril-treated group, respectively. The doses ofjected to a 5/6 renal NX, consisting of the surgical exci-
sion of approximately 2/3 of the renal cortex of the right candesartan cilexetil and enalapril (1 and 10 mg/kg, re-
spectively) used in the experiments were chosen becausekidney. One week later, the left kidney was removed.
As shown in Figure 1, drugs were administered once a they have been shown to provide equivalent hypotensive
effects in spontaneously hypertensive rats [22]. At theday in the morning beginning 15 weeks after the nephrec-
tomy, and the effects of drugs on the 4-week administra- end of both experiments, rats were anesthetized with
sodium pentobarbital (50 mg/kg, intraperitoneally), andtion (the short-term experiment) and the 16-week admin-
istration (the long-term experiment) were evaluated. a terminal blood sample was collected from the abdomi-
nal aorta. Then remnant kidneys of the 5/6 NX ratsThe short-term experiment consisted of the following
four groups: vehicle-treated (N 5 5), candesartan cilexe- and the right kidneys of the sham-operated rats were
removed and fixed in 10% neutral-buffered formalin fortil-treated (1 mg/kg, p.o., N 5 5), and enalapril-treated
(10 mg/kg, p.o., N 5 5) 5/6 NX rats, as well as sham- routine histological studies or were frozen for immuno-
histochemical studies. All animal experiments were per-operated normal two-kidney rats (N 5 3). The long-term
experiment consisted of following four groups: vehicle- formed according to the guidelines of the Takeda Experi-
mental Animal Care and Use Committee.treated (N 5 7), candesartan cilexetil-treated (1 mg/kg,
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Measurement of blood pressure were processed by the indirect immunoperoxidase tech-
nique. The number of glomeruli showing positive stain-Systolic blood pressure was measured five hours after
ing was expressed as a percentage of the total numberthe morning dose. Rats were maintained in individual
of glomeruli present in a specimen. A negative controlchambers warmed at 378C, and systolic blood pressure
value was obtained by replacing the primary antibodywas measured using a tail-cuff (PS-8000; Riken Kaihatsu,
with phosphate-buffered saline.Tokyo, Japan).
DrugsMeasurements of serum and urine parameters
Candesartan cilexetil (TCV-116), (6)-1-(cyclohexy-Twenty-four–hour urine samples were collected with
loxycarbonyloxy) ethyl 2-ethoxy-1-[[29-(1H-tetrazol-the aid of metabolic cages. Blood was collected from
5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-car-conscious rats via a tail vein using ethylenediaminetetra-
boxylate, and enalapril maleate were synthesized byacetic acid (EDTA) as an anticoagulant, and the plasma
Takeda Chemical Industries, Ltd. (Osaka, Japan).was stored below 2208C. Urinary total protein, urinary
albumin, urinary and plasma creatinine, and blood urea Statistical analysis
nitrogen (BUN) were measured by conventional meth-
Data are expressed as mean 6 se. Differences betweenods, using commercially available kits (Wako Pure
the vehicle-treated group and the sham-operated groupChemicals, Osaka, Japan). Plasma renin activity (PRA)
in values of urinary albumin excretion, total protein ex-was estimated as the activity of Ang I production from
cretion, systolic blood pressure, CCr, plasma creatinine,endogenous angiotensinogen using a radioimmunoassay
BUN, hematocrit, body weight, and kidney wet weightkit (SRL, Tokyo, Japan). Urinary prostaglandin E2 were analyzed by Student’s t-test. Differences between(PGE2) was extracted from 24-hour urine samples ac- the vehicle-treated group and the drug-treated groupscording to the method of Powell [23]. In brief, the urine
for all parameters were analyzed by Dunnett’s test. Be-was acidified to pH 3 with 1 N HCl and was passed
cause the variance homogeneity criterion of the paramet-through Sep-pak light C18 cartridges (Millipore, Bed-
ric test was not fulfilled in all data, the logarithm scale
ford, MA, USA), and PGE2 was eluted with ethanol/ transformation was applied to homogenize variances
water (15:85). The amount of the extracted PGE2 was where necessary, and the transformed data were used in
measured using an enzyme immunoassay kit (Amer- the analysis. A P , 0.05 was considered to indicate a
sham, Tokyo, Japan). In the long-term experiment, he- significant difference.




The kidneys were fixed in 10% neutral-buffered for- Figure 2 shows urinary total protein excretion (Fig.
malin and were embedded in paraffin. Sections of 4 mm 2A) and urinary albumin excretion (Fig. 2B) in both the
in thickness were stained with hematoxylin and eosin short- and long-term experiments. Urinary total protein
(H&E), periodic acid-methenamine silver (PAM), and and urinary albumin excretion in the vehicle-treated rats
Azan for the evaluation of glomerulosclerosis and tubu- increased with time, and the severity of the proteinuria
lointerstitial lesions. For each rat, all glomerular cross- began to increase sharply eight weeks after the first dose
sections present in a specimen were evaluated, and the in the long-term experiment. Candesartan cilexetil and
percentage of glomeruli exhibiting focal or global glo- enalapril significantly prevented the progression of pro-
merulosclerosis was determined. Glomerulosclerosis was teinuria in both experiments, and the effects of the two
evidenced by segmental increases in the glomerular ma- compounds were comparable.
trix, segmental collapse of capillary lumina, and/or adhe-
Blood pressuresion to Bowman’s capsule. Tubulointerstitial lesions
were defined as mononuclear cell infiltration and intersti- The 5/6 nephrectomy resulted in the development of
tial fibrosis. Lesions were assessed using the following systemic hypertension (Fig. 3). In the short-term experi-
scale: 0 5 normal, 1 5 small focal lesion, 2 5 multifocal ment, candesartan cilexetil tended to show a hypotensive
lesion, 3 5 diffuse lesion, and 4 5 extensive lesion involv- effect, and enalapril significantly decreased the systolic
ing the entire cortex. To examine the expression of trans- blood pressure (124.3 6 2.2, 149.4 6 4.0, 140.4 6 4.7,
forming growth factor-b1 (TGF-b1) in glomeruli, an im- and 129.0 6 4.8 mm Hg for sham operated, vehicle,
munohistochemical study was performed. Sections of candesartan cilexetil, and enalapril, respectively). In the
fresh frozen tissue (12 mm thick) were incubated with long-term experiment, both candesartan cilexetil and en-
a mouse monoclonal antibody against human TGF-b1 alapril showed significant and comparable antihyperten-
sive effects at the end of the 16-week administration(Antigenix America Inc., New York, NY, USA) and
Noda et al: Long-term renoprotection by TCV-116 901
Fig. 2. Effects of candesartan cilexetil and
enalapril on urinary total protein (A) and al-
bumin (B) excretion in 5/6 nephrectomized
rats. Symbols are: (d) vehicle; (m) candesar-
tan cilexetil 1 mg/kg; (j) enalapril 10 mg/kg;
(s) sham operated; §P , 0.05, §§P , 0.01
vs. sham-operated rats (sham operated) with
Student’s t-test; #P , 0.05, ##P , 0.01 vs.
vehicle-treated rats (vehicle) with Dunnett’s
test. Data are presented as mean 6 se.
Fig. 3. Effects of candesartan cilexetil and
enalapril on systolic blood pressure in 5/6 ne-
phrectomized rats. Symbols are: (d) vehicle;
(m) candesartan cilexetil 1 mg/kg; (j) enala-
pril 10 mg/kg; (s) sham operated; §§P , 0.01
vs. sham-operated rats (sham operated) with
Student’s t-test; #P , 0.05, ##P , 0.01 vs.
vehicle-treated rats (vehicle) with Dunnett’s
test. Data are presented as mean 6 se.
period (137.0 6 2.3, 151.9 6 2.6, 127.7 6 5.9, and 121.6 6 of glomeruli with sclerotic lesions markedly increased,
and interstitial fibrosis and mononuclear cell infiltration5.1 mm Hg for sham operated, vehicle, candesartan cilex-
etil and enalapril, respectively). were also observed. Both candesartan cilexetil and enala-
pril inhibited the progression of glomerulosclerosis and
Histological findings tended to prevent the interstitial fibrosis and mononu-
clear cell infiltration.Table 1 shows the histological findings in the short-
term experiment. In the vehicle-treated rats, the number Figures 4 and 5 show representative histological sec-
Fig. 4. Effects of candesartan cilexetil and enalapril on the glomerulosclerosis in 5/6 nephrectomized rats in the long-term experiment. Photomicro-
graphs of periodic acid-methenamine silver-stained preparations (magnification 3105) show glomeruli from a sham-operated rat (A), a vehicle-
treated rat (B), a candesartan cilexetil (1 mg/kg/day, p.o.)-treated rat (C), and an enalapril (10 mg/kg/day, p.o.)-treated rat (D).
Fig. 5. Effects of candesartan cilexetil and enalapril on the interstitial fibrosis in 5/6 nephrectomized rats in the long-term experiment. Microphoto-
graphs of AZAN-stained preparations (magnification 321) show glomerular and tubulointerstitial regions from a sham-operated rat (A), a vehicle-
treated rat (B), a candesartan cilexetil (1 mg/kg/day, p.o.)-treated rat (C), and an enalapril (10 mg/kg/day, p.o.)-treated rat (D).
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Table 1. Effects of candesartan cilexetil and enalapril on renal injury in 5/6 nephrectomized rats at the end of the short-term experiment
Sham op. Vehicle Candesartan cilexetil Enalapril
Glomerulosclerosis % 0.860.3 25.564.4 12.3 63.1a 8.762.7b
TGF-b1 expression % 0.060.0 25.365.0 7.9 64.2a 2.260.6b
Interstitial fibrosis (score) 0.060.0 2.6 60.2 1.6 60.4 1.860.4
MNC interstitial infiltration (score) 0.060.0 2.4 60.4 2.0 60.3 2.060.3
Data are presented as mean 6 se. Abbreviations are: op., operated; TGF-b1, transforming growth factor-beta1; MNC, mononeuclear cell.
a P , 0.05, b P , 0.01 vs. vehicle-treated rats (vehicle) with Dunnett’s test
tions of glomeruli and interstitial areas, respectively, in Urinary prostaglandin E2 excretion
the long-term experiment. Prominent glomerulosclerosis As shown in Figure 10, urinary PGE2 excretion in the
(Fig. 4) and severe interstitial fibrosis (Fig. 5) were ob- enalapril-treated 5/6 NX rats was markedly increased at
served in the vehicle-treated rats. ED1-positive inflam- the end of the 16-week administration period.
matory cells (macrophages) were also observed in both
Renal physiological parametersthe glomeruli and interstitial areas (data not shown).
Creatinine clearance, plasma creatinine, BUN, kidneyFigure 6 shows the quantitative analysis of these histolog-
weight, and body weight at the end of the short-termical findings. Candesartan cilexetil significantly inhibited
experiment, and hematocrit in addition to these parame-the progression of the glomerulosclerosis (1.0 6 0.4,
ters at the end of the long-term experiment were shown25.9 6 4.4, 9.7 6 3.2, and 15.2 6 4.6% for sham operated,
in Table 2. In vehicle-treated groups, a significant in-vehicle, candesartan cilexetil, and enalapril-treated
crease in plasma creatinine and BUN levels were ob-groups, respectively; Fig. 6A) and interstitial fibrosis
served in the short-term experiment. Both drugs had no(0.0 6 0.0, 3.3 6 0.2, 1.9 6 0.3, and 2.6 6 0.2 score
effect on these renal physiological parameters. At thefor sham operated, vehicle, candesartan cilexetil, and
end of the long-term experiment, a significant decreaseenalapril-treated groups, respectively; Fig. 6B), whereas
in CCr and an increase in plasma creatinine and BUN inenalapril did not show significant preventive effects.
the vehicle-treated group were observed. Neither drug
Both drugs inhibited the mononuclear cell infiltration inhibited these adverse changes significantly. The hema-
comparatively (0.0 6 0.0, 3.6 6 0.2, 2.1 6 0.3, and 2.1 6 tocrit value in the vehicle-treated rats decreased as com-
0.3 score for sham operated, vehicle-treated, candesartan pared with that in the sham-operated rats and was not
cilexetil-treated, and enalapril-treated groups, respec- affected by either drug at the end of long-term experi-
tively; Fig. 7). Immunoreactive TGF-b1 was expressed ment. The wet weight of the remnant kidney in the vehi-
in the glomeruli of the vehicle-treated rats, and the area cle-treated rats was higher than that of the normal right
of expression was comparable to the location of sclerotic kidney in the sham-operated rats. Neither drug had any
lesions (Fig. 8). TGF-b1 expression could not be detected effect on kidney weight in both of the experiments. Fig-
in the interstitium. Figure 9 shows the quantitative analy- ure 11 shows PRA in the short-term experiments. PRA
in the vehicle-treated rats showed a significant decreasesis of the glomerular TGF-b1 expression in both short-
as compared with the value in the sham-operated rats.and long-term experiments. The number of glomeruli
PRA in the candesartan cilexetil- and enalapril-treatedshowing TGF-b1 expression in the vehicle-treated rats
rats was increased significantly as compared with that inincreased with time. Candesartan cilexetil and enalapril
the vehicle-treated rats.significantly inhibited the expression of TGF-b1 in the
glomeruli in the short-term experiment (0.0 6 0.0, 25.3 6
5.0, 7.9 6 4.2, and 2.2 6 0.6% for sham operated, vehicle- DISCUSSION
treated, candesartan cilexetil-treated, and enalapril- The aim of this study was to compare the renal protec-
treated groups, respectively). In the long-term experi- tive effects of candesartan cilexetil, an AT1A, and enala-
ment, candesartan cilexetil markedly prevented the pril, an ACEI, on 4-week (short-term) and 16-week
increase in the expression of TGF-b1, whereas the pre- (long-term) administration during the progressive phase
ventive effect of enalapril decreased as compared with of renal injury in 5/6 NX rats. Drugs were administered
that in the short-term experiment, and a significant effect to 5/6 NX rats starting 15 weeks after the nephrectomy.
was not observed in the enalapril-treated rats (3.9 6 1.9, In the short-term experiment, candesartan cilexetil and
37.4 6 6.4, 10.4 6 2.1, and 23.7 6 8.7% for sham oper- enalapril showed marked renal protective effects. Both
ated, vehicle-treated, candesartan cilexetil-treated, and drugs suppressed proteinuria and glomerulosclerosis
(Fig. 2 and Table 1). These results coincided with theenalapril-treated groups, respectively).
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Fig. 6. Quantitative analysis of the effects of
candesartan cilexetil and enalapril on the glo-
merulosclerosis (A) and the interstitial fibrosis
(B) in 5/6 nephrectomized rats in the long-
term experiment. #P , 0.05; ##P , 0.01 vs.
vehicle-treated rats (vehicle) with Dunnett’s
test. Data are presented as mean 6 se.
proteins in glomeruli [26]. Therefore, the accumulation
of BK might induce the expression of TGF-b1 in mesan-
gial cells. It has also been reported that Ang II directly
induces the expression of TGF-b1 in cultured mesangial
cells [2]. In this study, candesartan cilexetil markedly
inhibited the enhanced expression of TGF-b1 in the in-
jured glomeruli. However, the suppressive effect of ena-
lapril on TGF-b1 expression decreased in the long-term
experiment. These results suggest that the weakness of
the inhibitory effect of enalapril on TGF-b1 expression
is caused by the accumulation of BK. In this study, we
did not measure the content of BK in the kidney, but
urinary PGE2 excretion, which is induced by BK in the
kidney [27], increased significantly in only the enalapril-
treated 5/6 NX rats in the long-term experiment (Fig.
Fig. 7. Effects of candesartan cilexetil and enalapril on the interstitial
10), suggesting the accumulation of BK in the kidney.mononuclear cell infiltration in 5/6 nephrectomized rats in the long
term experiment. ##P , 0.01 vs. vehicle-treated rats (vehicle) with The level of urinary PGE2 excretion in vehicle-treated
Dunnett’s test. Data are presented as mean 6 se. group was lower than that of the sham-operated group.
It is conceivable that this reduction might be caused by
the decrease in PGE2-producing cells of the remnant
kidney because of both the initial renal ablation and theresults of many previous studies designed to examine
progression of injuries. Enalapril markedly increased thethe renoprotective effects of earlier treatment with
urinary PGE2 excretion compared with vehicle; there-AT1As and ACEIs in 5/6 NX rats [4–9, 24]. In the long-
fore, the elevation of the PGE2 excretion by enalaprilterm experiment, candesartan cilexetil significantly
might be caused in part by the accumulation of BK.ameliorated the progression of glomerulosclerosis, the
Because glomerular capillary hypertension induces glo-glomerular expression of immunoreactive TGF-b1, and
merular dysfunction, the amelioration of glomerular cap-interstitial fibrosis, but enalapril did not, although both
illary hypertension via a reduction of efferent arteriolardrugs showed the same hypotensive and antiproteinure-
tone is thought to prevent the development of glomeru-mic effects. The differences between candesartan cilexe-
lar injury [4–7]. It has been reported that the antagonismtil and enalapril with regard to renal protective effects
of Ang II with an AT1A causes less reduction in themay be explained as follows.
glomerular efferent arteriolar tone than the inhibitionFirst, the inhibition of ACE, namely, kininase II, by
of ACE with an ACEI, because the accumulated BKan ACEI results in the accumulation of BK [15]. As BK
causes efferent arteriole dilation [28, 29]. This suggestsstimulates the proliferation of cultured rat mesangial
that BK contributes to the renoprotective effects ofcells [25], and as the proliferation of mesangial cells plays
ACEIs; however, in our study, enalapril did not showan important role in the progression of glomerulosclero-
any advantage over candesartan cilexetil.sis, this effect of BK might counteract the renal protective
Second, an AT1A can completely inhibit Ang II’s ef-effects of ACEIs. BK also activates AP-1 [25], one of
fects at the level of AT1 receptors, whereas enalaprilthe major transcriptional factors of TGF-b1, which plays
a pivotal role in the accumulation of extracellular matrix cannot inhibit the effect of Ang II produced by proteases
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Fig. 8. Expression of immunoreactive transforming growth factor-b1 (TGF-b1) in a glomerulus from a sham-operated rat (A) and a 5/6 nephrecto-
mized rat (B) at the end of the long-term experiment (magnification 3210).
Fig. 9. Quantitative analysis of the effects of
candesartan cilexetil and enalapril on the glo-
merular expression of transforming growth
factor-b1 (TGF-b1) in 5/6 nephrectomized
rats in the (A) short- and (B) long-term ex-
periments. #P , 0.05; ##P , 0.01 vs. vehicle-
treated rats (vehicle) with Dunnett’s test. Data
are presented as mean 6 se.
other than ACE. In some organs, ACE-independent nals [13]. Because AT2 receptors exist in the kidney of
adult rats [34], activation of AT2 receptors might haveAng I conversion is predominant in the generation of
Ang II [30, 31]. Urata, Strobel, and Ganten reported that contributed to the beneficial renal protective effects of
candesartan cilexetil, especially in the long-term experi-chymase, an ACEI-insensitive Ang II-forming protease,
exists in the human renal cortex [32]. In the rat kidney, ment. According to a recent report, however, indirect
AT2 receptor activation stimulates the glomerular infil-some Ang II-forming pathways other than that involving
ACE exist, and these may have contributed to the failure tration of monocytes/macrophages via RANTES expres-
sion, resulting in the progression of renal injury [35].of the renoprotective effects of enalapril in the long-
term experiment. For instance, cathepsin G contained However, in this study, AT2 receptor activation did not
seem to be an important factor for the infiltration ofin infiltrating monocytes can generate Ang II from angio-
tensinogen directly [33]. inflammatory cells because candesartan cilexetil and ena-
lapril caused comparable inhibition of interstitial mono-Third, AT1As are reported to activate AT2 receptors
via the elevation of plasma Ang II [16]. As AT2 receptors nuclear cell infiltration.
It has been established that the augmented productionmediate antiproliferative and antifibrotic effects, AT1
and AT2 receptors might mediate counterbalancing sig- of TGF-b1 is important in the progression of interstitial
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Fig. 10. Effects of candesartan cilexetil and enalapril on urinary prosta-
glandin E2 (PGE2) excretion in 5/6 nephrectomized rats in the long-
term experiment. ##P , 0.01 vs. vehicle-treated rats (vehicle) with
Fig. 11. Effects of candesartan cilexetil and enalapril on plasma reninDunnett’s test. Data are presented as mean 6 se.
activity (PRA) in 5/6 nephrectomized rats in the short-term experi-
ments. The open diamonds and closed squares indicate individual values
and mean values for PRA, respectively. §P , 0.05 vs. sham-operated
rats (sham op.) with Student’s t-test. #P , 0.05; ##P , 0.01 vs. vehicle-
treated rats (vehicle) with Dunnett’s test. Data are presented as
mean 6 se.
Table 2. Effects of candesartan cilexetil and enalapril on creatinine clearance (CCr, plasma creatinine, blood urea nitrogen (BUN), hematocrit,
kidney wet weight and body weight in 5/6 NX rats at the end of both experiments
Sham op. Vehicle Candesartan cilexetil Enalapril
Short-term
CCr ml/min/100g body wt 0.3860.03 0.31 60.02 0.3060.02 0.29 60.03
Plasma creatinine mg/dl 0.5960.05 0.93 60.02a 0.8960.04 0.99 60.06
BUN mg/dl 21.760.8 47.3 62.0a 44.463.6 51.5 64.4
Kidney weight g/100g body wt 0.2860.03c 0.4160.02a 0.4160.03 0.39 60.01
Body weight g 655.068.7 628.0 624.1 619.8629.8 620.0 621.4
Long-term
CCr ml/min/100g body wt 0.4760.05 0.22 60.02a 0.2660.03 0.20 60.03
Plasma creatinine mg/dl 0.6260.06 1.64 60.26a 1.2360.12 1.96 60.44
BUN mg/dl 17.561.3 74.7 65.4a 59.665.7 69.8 68.5
Hematocrit % 44.160.3 34.1 61.6a 34.961.2 31.7 61.7
Kidney weight g/100g body wt 0.2560.01c 0.4260.02a 0.3660.03 0.39 60.03
Body weight g 755.0621.2 673.4 64.8b 639.0612.7 632.6 620.6
Data are presented as mean 6 se.
a P , 0.01, b P , 0.05 vs. sham operated rats (Sham op.) with Student’s t-test
c The wet weight of the intact right kidney
fibrosis as well as glomerulosclerosis [24, 36–39]. In this AT1 receptors, which are expressed in the same cells
[42], PRA seems to be an indicator of the extent of RASstudy, the expression of TGF-b1 in the interstitium was
not observed. Wu et al reported that the expression of inhibition. After the four-week administration of both
drugs in the short-term experiment, PRA increased toTGF-b1 mRNA was detected in sclerotic glomeruli, areas
of tubulointerstitial injury, and sites of mononuclear cell the same level, indicating that the extent of RAS inhibi-
tion by the two drugs was the same.infiltration by in situ hybridization for TGF-b1 mRNA
[24]. Muchaneta-Kubara, Sayed-Ahmed, and Nahas also Despite marked improvements of proteinuria and his-
topathological changes, candesartan cilexetil did notreported that immunoreactive TGF-b1 expression in the
interstitium was observed in the remnant kidney of 5/6 show a significant effect on renal function, demonstrated
by CCr, plasma creatinine, and BUN. It was reported thatNX rats [40]. On the other hand, it has been reported
that positive staining of TGF-b1 was seen in the injured the progression rate of decrease in renal function was
slower than the changes of proteinuria and histopathol-glomeruli but not in the interstitium [41]. The reason for
these differences remains unclear. ogy [43]. In our study, the marked decrease in renal
function was not observed during the intervention, evenThe inhibition of the RAS by AT1As and ACEIs ele-
vates PRA [42]. As renin is produced in juxtaglomerular in the long-term experiment. As candesartan cilexetil
significantly inhibited both proteinuria and histopatho-cells and secretion is regulated by the blockade of the
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of transforming growth factor-b expression in rat glomerular mes-logical changes and tended to improve the adverse
angial cells. J Clin Invest 93:2431–2437, 1994
changes of CCr, plasma creatinine, and BUN, the more 3. Matsusaka T, Hymes J, Ichikawa I: Angiotensin in progressive
renal diseases: Theory and practice. J Am Soc Nephrol 7:2025–2043,prolonged follow-up may be helpful to clarify the prefer-
1996ential benefits of candesartan cilexetil on renal function.
4. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control
One of the aims of this study was to investigate of glomerular hypertension limits glomerular injury in rats with
reduced renal mass. J Clin Invest 76:612–619, 1985whether the AT1 antagonists and ACE inhibitors would
5. Anderson S, Rennke HG, Brenner BM: Therapeutic advantageshow differential renal protective effects. Very recently,
of converting enzyme inhibitors in arresting progressive renal dis-
Taal and Brenner reported that a 24-week treatment of ease associated with systemic hypertension in the rat. J Clin Invest
77:1993–2000, 1986candesartan cilexetil and enalapril equally reduced the
6. Mackenzie HS, Troy JL, Rennke HG, Brenner BM: TCV-116progression of previously developed renal injury in 5/6
prevents progressive renal injury in rats with extensive renal mass
NX Munich Wistar rats [44]. In our study, significant ablation. J Hypertens 12(Suppl 9):S11–S16, 1994
7. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin IIdifferences were not documented between the beneficial
receptor blockade limits glomerular injury in rats with reducedeffects of candesartan cilexetil and enalapril, although
renal mass. J Clin Invest 90:766–771, 1992
enalapril did not show significant effects on glomerulo- 8. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I,
Fogo A: Blood pressure-independent effect of angiotensin inhibi-sclerosis and tubular interstitial fibrosis in the long-term
tion on vascular lesions of chronic renal failure. Kidney Int 42:46–experiments. A more prolonged follow-up study may be 55, 1992
necessary to clarify this puzzle. 9. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ: Angio-
tensin II receptor blockade improves renal function in rats withIn conclusion, the renal protective effects of candesar-
reduced renal mass. J Pharmacol Exp Ther 267:657–663, 1993tan cilexetil and enalapril were examined during the pro- 10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of
gressive phase of renal injury in 5/6 NX rats. Four-week angiotensin-converting-enzyme inhibition on diabetic nephropa-
thy. N Engl J Med 329:1456–1462, 1993treatment with the two drugs showed renal protective
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angiotensin and bradykinin peptide and angiotensin-convertingThus, the AT1 receptor antagonist candesartan cilexetil
enzyme. J Cardiovasc Pharmacol 26:233–240, 1995may be very useful for long-term treatment of patients 13. Dzau VJ, Muroyama M, Pratt RE: Molecular biology of angioten-
with chronic renal failure. sin receptor: Target for drug research? J Hypertens 12(Suppl 2):S1–
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